SC
MYGN icon

Schubert & Co’s Myriad Genetics MYGN Stock Holding History

Schubert & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39
Closed -$906 – 973
2023
Q1 		$906 Buy
39
+10
+34% +$203 ﹤0.01% 1230
2022
Q4 		$421 Sell
29
-3
-9% -$56 ﹤0.01% 1428
2022
Q3 		$1K Buy
32
+3
+10% +$69 ﹤0.01% 1176
2022
Q2 		$1K Buy
29
+19
+190% +$395 ﹤0.01% 1202
2022
Q1 		$0 Buy
10
+5
+100% +$128 ﹤0.01% 1240
2021
Q4 		$0 Buy
+5
New +$145 ﹤0.01% 1185

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Schubert & Co's MYGN Position: Q2 2023 in Review

Schubert & Co sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 39 shares — an estimated $906 sold.

Schubert & Co first reported a position in MYGN in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

  • Schubert & Co reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 39 Myriad Genetics shares in Q2 2023, an estimated $906.
  • Schubert & Co first reported a position in Myriad Genetics in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Myriad Genetics position peaked at $1K in Q3 2022.
  • 188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.